Download PDF
Semin Thromb Hemost 2011; 37(8): 897-902
DOI: 10.1055/s-0031-1297368
© Thieme Medical Publishers

Dyslipidemia, Statins, and Venous Thromboembolism

Pavel Poredos1 , Mateja Kaja Jezovnik1
  • 1Department of Vascular Disease, Ljubljana University Medical Centre, Ljubljana, Slovenia
Further Information

Publication History

Publication Date:
23 December 2011 (online)

    Permissions and Reprints

ABSTRACT

Venous thromboembolism (VTE) is one of the most frequent and serious vascular diseases. Although the major risk factors of VTE are well recognized, the pathology often develops in subjects without any obvious precipitating factor. Recent evidence suggests a link between arterial and venous thrombosis, particularly in patients with idiopathic venous thrombosis. Therefore, similar or identical risk factors may play a role in the development of both diseases. A positive association between classical risk factors of atherosclerosis, including dyslipidemia, and VTE has been reported. Recent studies demonstrated an association between hypercholesterolemia and objectively verified VTE. Circulating lipids have been shown to have both prothrombotic- and endothelium-deteriorating properties. Studies suggested a greater generation of thrombin, endothelial dysfunction, and higher platelet activity in hyperlipidemic blood. By impeding these mechanisms, statins may protect against VTE. Observational, controlled studies and two meta-analyses showed that statins significantly reduced VTE risk, most likely in a process independent from cholesterol lowering, through mechanisms related to the pleiotropic effects of these drugs. Currently, it is unknown whether VTE prevention is a class-effect of statins, or if statins differ in their antithrombotic efficacy, and it is also unknown if statin benefit is dose-dependent. However, there are also opposite findings about the efficacy of statins in prevention of VTE. Therefore, the use of statins for prophylaxis of VTE cannot be generally recommended at this stage. Further studies are needed to identify those patients who could eventually benefit maximally from treatment with statins for prevention of VTE.

KEYWORDS

Venous thrombosis - statins - inflammation - coagulation - dyslipidemia

REFERENCES

  • 1 Lijfering W M, Flinterman L E, Vandenbroucke J P, Rosend F R, Cannegieter S C. Relationship between venous and arterial thrombosis: a review of the literature from a causal perspective.  Semin Thromb Hemost. 2011;  37 (8) 885-896
    Google Scholar
  • 2 Jezovnik M K, Poredos P, Stalc M. Impairment of the vasodilatation capability of the brachial artery in patients with idiopathic venous thrombosis.  J Atheroscler Thromb. 2010;  17 (11) 1190-1198
    Google Scholar
  • 3 Prandoni P, Bilora F, Marchiori A et al.. An association between atherosclerosis and venous thrombosis.  N Engl J Med. 2003;  348 (15) 1435-1441
    Google Scholar
  • 4 Jezovnik M K, Poredos P, Lusa L. Idiopathic venous thrombosis is associated with preclinical atherosclerosis.  J Atheroscler Thromb. 2010;  17 (3) 304-311
    Google Scholar
  • 5 Prandoni P, Ghirarduzzi A, Prins M H et al.. Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis.  J Thromb Haemost. 2006;  4 (9) 1891-1896
    Google Scholar
  • 6 Ageno W, Dentali F. Venous thromboembolism and arterial thromboembolism. Many similarities, far beyond thrombosis per se.  Thromb Haemost. 2008;  100 (2) 181-183
    Google Scholar
  • 7 Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen P W. Cardiovascular risk factors and venous thromboembolism: a meta-analysis.  Circulation. 2008;  117 (1) 93-102
    Google Scholar
  • 8 Goldhaber S Z, Savage D D, Garrison R J et al.. Risk factors for pulmonary embolism. The Framingham Study.  Am J Med. 1983;  74 (6) 1023-1028
    Google Scholar
  • 9 Goldhaber S Z, Grodstein F, Stampfer M J et al.. A prospective study of risk factors for pulmonary embolism in women.  JAMA. 1997;  277 (8) 642-645
    Google Scholar
  • 10 Kawasaki T, Kambayashi J, Ariyoshi H, Sakon M, Suehisa E, Monden M. Hypercholesterolemia as a risk factor for deep-vein thrombosis.  Thromb Res. 1997;  88 (1) 67-73
    Google Scholar
  • 11 Nowak-Göttl U, Junker R, Hartmeier M et al.. Increased lipoprotein(a) is an important risk factor for venous thromboembolism in childhood.  Circulation. 1999;  100 (7) 743-748
    Google Scholar
  • 12 Ignatescu M, Kostner K, Zorn G et al.. Plasma Lp(a) levels are increased in patients with chronic thromboembolic pulmonary hypertension.  Thromb Haemost. 1998;  80 (2) 231-232
    Google Scholar
  • 13 Lippi G, Brocco G, Manzato F, Guidi G. Relationship between venous thromboembolism and lipid or lipoprotein disorders.  Thromb Res. 1999;  95 (6) 353-354
    Google Scholar
  • 14 von Depka M, Nowak-Göttl U, Eisert R et al.. Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism.  Blood. 2000;  96 (10) 3364-3368
    Google Scholar
  • 15 Lippi G, Bassi A, Brocco G, Manzato F, Marini M, Guidi G. Lipoprotein(a) concentration is not associated with venous thromboembolism in a case control study.  Haematologica. 1999;  84 (8) 726-729
    Google Scholar
  • 16 McColl M D, Sattar N, Ellison J et al.. Lipoprotein (a), cholesterol and triglycerides in women with venous thromboembolism.  Blood Coagul Fibrinolysis. 2000;  11 (3) 225-229
    Google Scholar
  • 17 Ray J G, Rosendaal F R. The role of dyslipidemia and statins in venous thromboembolism.  Curr Control Trials Cardiovasc Med. 2001;  2 (4) 165-170
    Google Scholar
  • 18 Volpato S, Palmieri E, Fellin R, Zuliani G. Acute phase markers are associated with reduced plasma lipid levels in a population of hospitalized elderly patients.  Gerontology. 2000;  46 (1) 22-27
    Google Scholar
  • 19 Sattar N, Petrie J R, Jaap A J. The atherogenic lipoprotein phenotype and vascular endothelial dysfunction.  Atherosclerosis. 1998;  138 (2) 229-235
    Google Scholar
  • 20 Cignarella A, Mussoni L, Mannucci L, Ferioli E, Puglisi L, Tremoli E. Platelet activation supports the development of venous thrombosis in hyperlipidemic rats.  Blood Coagul Fibrinolysis. 1998;  9 (1) 47-53
    Google Scholar
  • 21 Dzeka T N, Derylo B, Arnold JMO. Endothelial function and statins in human veins.  Can J Cardiol. 2000;  16 193F
    Google Scholar
  • 22 Bladbjerg E M, Marckmann P, Sandström B, Jespersen J. Non-fasting factor VII coagulant activity (FVII:C) increased by high-fat diet.  Thromb Haemost. 1994;  71 (6) 755-758
    Google Scholar
  • 23 Scanu A M. Lipoprotein(a). A genetic risk factor for premature coronary heart disease.  JAMA. 1992;  267 (24) 3326-3329
    Google Scholar
  • 24 Lippi G, Franchini M, Guidi G C. Lipoprotein(a), athero-thrombosis and longevity. A historical paradox finally elucidated?.  Haematologica. 2007;  92 (4) e48
    Google Scholar
  • 25 Ridker P M, Danielson E, Fonseca F A JUPITER Study Group et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.  N Engl J Med. 2008;  359 (21) 2195-2207
    Google Scholar
  • 26 Heart Protection Study Collaborative Group . MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.  Lancet. 2002;  360 (9326) 7-22
    Google Scholar
  • 27 Undas A, Brummel-Ziedins K E, Mann K G. Statins and blood coagulation.  Arterioscler Thromb Vasc Biol. 2005;  25 (2) 287-294
    Google Scholar
  • 28 Herrington D M, Vittinghoff E, Lin F HERS Study Group et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS).  Circulation. 2002;  105 (25) 2962-2967
    Google Scholar
  • 29 Ramcharan A S, Van Stralen K J, Snoep J D, Mantel-Teeuwisse A K, Rosendaal F R, Doggen C J. HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis.  J Thromb Haemost. 2009;  7 (4) 514-520
    Google Scholar
  • 30 Sørensen H T, Horvath-Puho E, Søgaard K K et al.. Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study.  J Thromb Haemost. 2009;  7 (4) 521-528
    Google Scholar
  • 31 Ray J G, Mamdani M, Tsuyuki R T, Anderson D R, Yeo E L, Laupacis A. Use of statins and the subsequent development of deep vein thrombosis.  Arch Intern Med. 2001;  161 (11) 1405-1410
    Google Scholar
  • 32 Smeeth L, Douglas I, Hall A J, Hubbard R, Evans S. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials.  Br J Clin Pharmacol. 2009;  67 (1) 99-109
    Google Scholar
  • 33 Glynn R J, Danielson E, Fonseca F A et al.. A randomized trial of rosuvastatin in the prevention of venous thromboembolism.  N Engl J Med. 2009;  360 (18) 1851-1861
    Google Scholar
  • 34 Agarwal V, Phung O J, Tongbram V, Bhardwaj A, Coleman C I. Statin use and the prevention of venous thromboembolism: a meta-analysis.  Int J Clin Pract. 2010;  64 (10) 1375-1383
    Google Scholar
  • 35 Squizzato A, Galli M, Romualdi E et al.. Statins, fibrates, and venous thromboembolism: a meta-analysis.  Eur Heart J. 2010;  31 (10) 1248-1256
    Google Scholar
  • 36 Lacut K, Le Gal G, Abalain J H, Mottier D, Oger E. Differential associations between lipid-lowering drugs, statins and fibrates, and venous thromboembolism: role of drug induced homocysteinemia?.  Thromb Res. 2008;  122 (3) 314-319
    Google Scholar
  • 37 Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis.  Am J Med. 2008;  121 (10, Suppl 1) S21-S31
    Google Scholar
  • 38 Jezovnik M K, Poredos P. Idiopathic venous thrombosis is related to systemic inflammatory response and to increased levels of circulating markers of endothelial dysfunction.  Int Angiol. 2010;  29 (3) 226-231
    Google Scholar
  • 39 Lippi G, Favaloro E J, Montagnana M, Franchini M. C-reactive protein and venous thromboembolism: causal or casual association?.  Clin Chem Lab Med. 2010;  48 (12) 1693-1701
    Google Scholar
  • 40 Ray K K, Cannon C P. Early time to benefit with intensive statin treatment: could it be the pleiotropic effects?.  Am J Cardiol. 2005;  96 (5A) 54F-60F
    Google Scholar
  • 41 Albert M A, Danielson E, Rifai N, Ridker P M. PRINCE Investigators . Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.  JAMA. 2001;  286 (1) 64-70
    Google Scholar
  • 42 Jezovnik M K, Poredos P, Stalc M. Impairment of the vasodilatation capability of the brachial artery in patients with idiopathic venous thrombosis.  J Atheroscler Thromb. 2010;  17 (11) 1190-1198
    Google Scholar
  • 43 Spring S, Simon R, van der Loo B et al.. High-dose atorvastatin in peripheral arterial disease (PAD): effect on endothelial function, intima-media-thickness and local progression of PAD. An open randomized controlled pilot trial.  Thromb Haemost. 2008;  99 (1) 182-189
    Google Scholar
  • 44 Yang Z, Kozai T, van der Loo B et al.. HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins.  J Am Coll Cardiol. 2000;  36 (5) 1691-1697
    Google Scholar
  • 45 Ali F Y, Armstrong P C, Dhanji A R et al.. Antiplatelet actions of statins and fibrates are mediated by PPARs.  Arterioscler Thromb Vasc Biol. 2009;  29 (5) 706-711
    Google Scholar
  • 46 Kröger N, Shimoni A, Zagrivnaja M et al.. Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma.  Blood. 2004;  104 (10) 3361-3363
    Google Scholar
  • 47 Undas A, Brummel K E, Musial J, Mann K G, Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation.  Circulation. 2001;  103 (18) 2248-2253
    Google Scholar
  • 48 Cortellaro M, Cofrancesco E, Arbustini E et al.. Atorvastatin and thrombogenicity of the carotid atherosclerotic plaque: the ATROCAP study.  Thromb Haemost. 2002;  88 (1) 41-47
    Google Scholar
  • 49 Doggen C J, Lemaitre R N, Smith N L, Heckbert S R, Psaty B M. HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women.  J Thromb Haemost. 2004;  2 (5) 700-701
    Google Scholar
  • 50 Keech A, Simes R J, Barter P FIELD study investigators et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.  Lancet. 2005;  366 (9500) 1849-1861
    Google Scholar
  • 51 Cervellin G, Comelli I, Lippi G. Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features.  Clin Chem Lab Med. 2010;  48 (6) 749-756
    Google Scholar

Pavel PoredosM.D. Ph.D. 

Full Professor of Internal Medicine, Department of Vascular Disease, Ljubljana University Medical Centre

Zaloska 7, SI-1000 Ljubljana, Slovenia

Email: pavel.poredos@kclj.si